Phase 1 study of CS-1008 [tigatuzumab], a humanized monoclonal antibody targeting death receptor 5 (DR5), administered weekly to patients with advanced solid malignancies and lymphomas (without leukemic component)

Trial Profile

Phase 1 study of CS-1008 [tigatuzumab], a humanized monoclonal antibody targeting death receptor 5 (DR5), administered weekly to patients with advanced solid malignancies and lymphomas (without leukemic component)

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Tigatuzumab (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 21 Jun 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top